Mostrar el registro sencillo de la publicación

dc.contributor.authorRojas, Armando
dc.contributor.authorSchneider, Iván
dc.contributor.authorLindner-Sanhueza, Cristian
dc.contributor.authorGonzález-Bonet, Ileana
dc.contributor.authorMorales, Miguel A.
dc.date.accessioned2022-01-03T18:50:05Z
dc.date.available2022-01-03T18:50:05Z
dc.date.issued2021
dc.identifier.urihttp://repositorio.ucm.cl/handle/ucm/3696
dc.description.abstractCompelling evidence supports the crucial role of the receptor for advanced glycation end-products (RAGE) axis activation in many clinical entities. Since the beginning of the coronavirus disease 2019 pandemic, there is an increasing concern about the risk and handling of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in inflammatory gastrointestinal disorders, such as inflammatory bowel diseases (IBD). However, clinical data raised during pandemic suggests that IBD patients do not have an increased risk of contracting SARS-CoV-2 infection or develop a more severe course of infection. In the present review, we intend to highlight how two potentially important contributors to the inflammatory response to SARS-CoV-2 infection in IBD patients, the RAGE axis activation as well as the cross-talk with the renin-angiotensin system, are dampened by the high expression of soluble forms of both RAGE and the angiotensin-converting enzyme (ACE) 2. The soluble form of RAGE functions as a decoy for its ligands, and soluble ACE2 seems to be an additionally attenuating contributor to RAGE axis activation, particularly by avoiding the transactivation of the RAGE axis that can be produced by the virus-mediated imbalance of the ACE/angiotensin II/angiotensin II receptor type 1 pathway.es_CL
dc.language.isoenes_CL
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 Chile*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/cl/*
dc.sourceWorld Journal of Gastroenterology, 27(19), 2270-2280es_CL
dc.subjectCOVID-19es_CL
dc.subjectInflammatory bowel diseaseses_CL
dc.subjectAdvanced glycationes_CL
dc.subjectAngiotensin-converting enzyme 2es_CL
dc.subjectAlarminses_CL
dc.subjectReceptor for advanced glycation end-productses_CL
dc.subjectReceptor for advanced glycation end-products axises_CL
dc.subjectInflammationes_CL
dc.titleReceptor for advanced glycation end-products axis and coronavirus disease 2019 in inflammatory bowel diseases: A dangerous liaison?es_CL
dc.typeArticlees_CL
dc.ucm.facultadFacultad de Medicinaes_CL
dc.ucm.indexacionScopuses_CL
dc.ucm.indexacionIsies_CL
dc.ucm.uriwww.wjgnet.com/1007-9327/full/v27/i19/2270.htmes_CL
dc.ucm.doidoi.org/10.3748/wjg.v27.i19.2270es_CL


Ficheros en la publicación

Vista Previa No Disponible
Thumbnail

Esta publicación aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo de la publicación

Atribución-NoComercial-SinDerivadas 3.0 Chile
Excepto si se señala otra cosa, la licencia de la publicación se describe como Atribución-NoComercial-SinDerivadas 3.0 Chile